Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers

Orlistat, a lipase inhibitor, acts locally in the gastrointestinal tract. Systemic absorption is not required for its efficacy, but knowledge of the extent of its systemic absorption is important for its safe use in obese patients, the intended target population. Pharmacokinetic screening was carried out by monitoring plasma concentrations of unchanged orlistat in 25 phase 1 studies (including two mass balance studies) in normal and obese healthy volunteers. The results of these studies indicate an extremely low degree of systemic absorption for orlistat when administered with a hypocaloric, well-balanced diet with 20% to 30% of calories derived from fat (50-80 gm). To further characterize the pharmacokinetics and excretion pathways of orlistat, two mass balance studies using 14C-labeled orlistat were conducted. After oral dosing of radiolabeled orlistat with a fatty meal (28-30 gm fat), almost the entire dose was recovered from fecal samples; little was found in plasma and urine. It is concluded that systemic absorption of orlistat is negligible; at a clinically efficacious dose level, orlistat is unlikely to produce systemic lipase inhibition.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Idelevich, W. Kirch, and C. Schindler Current pharmacotherapeutic concepts for the treatment of obesity in adults Therapeutic Advances in Cardiovascular Disease, February 1, 2009; 3(1): 75 - 90. [Abstract] [PDF]

				K. C. Dunican, A. R. Desilets, and R. J. DeBellis State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant American Journal of Lifestyle Medicine, October 1, 2007; 1(5): 367 - 388. [Abstract] [PDF]

				K. C Dunican, A. R Desilets, and J. K Montalbano Pharmacotherapeutic Options for Overweight Adolescents Ann. Pharmacother., September 1, 2007; 41(9): 1445 - 1455. [Abstract] [Full Text] [PDF]

				J.-P. Chanoine, S. Hampl, C. Jensen, M. Boldrin, and J. Hauptman Effect of Orlistat on Weight and Body Composition in Obese Adolescents: A Randomized Controlled Trial JAMA, June 15, 2005; 293(23): 2873 - 2883. [Abstract] [Full Text] [PDF]

				D. Cheng, T. C. Nelson, J. Chen, S. G. Walker, J. Wardwell-Swanson, R. Meegalla, R. Taub, J. T. Billheimer, M. Ramaker, and J. N. Feder Identification of Acyl Coenzyme A:Monoacylglycerol Acyltransferase 3, an Intestinal Specific Enzyme Implicated in Dietary Fat Absorption J. Biol. Chem., April 11, 2003; 278(16): 13611 - 13614. [Abstract] [Full Text] [PDF]

				F. Carriere, C. Renou, S. Ransac, V. Lopez, J. De Caro, F. Ferrato, A. De Caro, A. Fleury, P. Sanwald-Ducray, H. Lengsfeld, et al. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers Am J Physiol Gastrointest Liver Physiol, July 1, 2001; 281(1): G16 - G28. [Abstract] [Full Text] [PDF]

				R. De Smet, J. Van Kaer, H. Liebich, G. Lesaffer, A. Verstraete, A. Dhondt, P. Duym, N. Lameire, and R. Vanholder Heparin-induced Release of Protein-bound Solutes during Hemodialysis Is an in Vitro Artifact Clin. Chem., May 1, 2001; 47(5): 901 - 909. [Abstract] [Full Text] [PDF]

				G. A. Bray and F. L. Greenway Current and Potential Drugs for Treatment of Obesity Endocr. Rev., December 1, 1999; 20(6): 805 - 875. [Abstract] [Full Text]

				M. H. Davidson, J. Hauptman, M. DiGirolamo, J. P. Foreyt, C. H. Halsted, D. Heber, D. C. Heimburger, C. P. Lucas, D. C. Robbins, J. Chung, et al. Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat: A Randomized Controlled Trial JAMA, January 20, 1999; 281(3): 235 - 242. [Abstract] [Full Text] [PDF]